Summer Street recommending a short position or stay away long. Have heard borrowing PRAN shares difficult/expensive.
When was I *very negative* on REGN? Might have been quite some time since I have updated my view on here. Certainly think Eylea a good product and they're delivering with recent Bayer expanded collaboration. Think they may be coming a little late to the immuno-onc space.
Sanofi needs them, holding on tight. Dupi data in asthma was fantastic, less thrilled on RA program - crowded and not sure if differentiated enough. Difficult to judge PCSK9 potential revenues without knowing outcomes study result. Amgen will be stiff competition and moving to market quick.
I agree that Summer Street is a very good science/medical research shop. They did have foresight in ICPT.
Despite that, they had one big miss.
From SummerStreet 12/16/2013 report on ICPT:
The National Institutes of Health (NIH) is running a sizeable phase II trial in NASH. We find no compelling reason why OCA should be successful in NASH, and we believe the study is being run in part because ofthe tremendous public health threat associated with the disease and the lack of options. The trial is to be completed late in the second half of 2014.
News 
Market Data 
Discover 
AI
